The function of vitamin D in regulating the inflammation, proliferation, and differentiation of keratinocytes has led to the use of topical vitamin D analogs for the treatment of plaque psoriasis. Both calcipotriene, a synthetic form of vitamin D, and calcitriol, a naturally occurring form of vitamin D, are commonly prescribed topical agents that have demonstrated significant improvement in the treatment of mild to moderate plaque psoriasis compared with vehicle alone. The most effective use of vitamin D analogs for plaque psoriasis has been in combination with topical corticosteroids. The low side-effect profile of these topical vitamin D agents also makes them an important therapeutic option for plaque psoriasis. This article summarizes the major studies involving topical vitamin D analogs for plaque psoriasis with suggestions for areas of future study.
PillaiS., BikleD.D.Role of intracellular-free calcium in the cornified envelope formation of keratinocytes: differences in the mode of action of extracellular calcium and 1,25 dihydroxyvitamin D3. J Cell Physiol.1991; 146: 94–100.
2.
BikleD.D., PillaiS., GeeE.Squamous carcinoma cell lines produce 1,25 dihydroxyvitamin D, but fail to respond to its prodifferentiating effect. J Invest Dermatol.1991; 97: 435–41.
3.
HosomiJ., HosoiJ., AbeE., SudaT., KurokiT.Regulation of terminal differentiation of cultured mouse epidermal cells by 1-alpha, 25-dihydroxyvitamin D3. Endocrinology.1983; 113: 1950–7.
4.
SmithE.L., WalworthN.C., HolickM.F.Effect of 1-alpha, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol.1986; 86: 709–14.
5.
MclaneJ.A., KatzM., AbdelkaderN.Effect of 1,25-dihydroxyvitamin D3 on human keratinocytes grown under different culture conditions. In Vitro Cell Dev Biol.1990; 26: 379–87.
6.
HawkerN.P., PennypackerS.D., ChangS.M., BikleD.D.Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol.2007; 127: 874–80.
7.
MatsumotoK., HashimotoK., NishidaY., HashiroM., YoshikawaK.Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun.1990; 166: 916–23.
8.
BikleD.D., ChangS., CrumrineD.25-Hydroxyvitamin D 1-alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol.2004; 122: 984–92.
9.
KamenD.L., TangprichaV.Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl).2010; 88: 441–50.
GerritsenM.J., RuloH.F., Van Vlijmen-WillemsI., Van ErpP.E., Van de KerkhofP.C.Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. Br J Dermatol.1993; 128: 666–73.
El-DomyatiM., BarakatM., Abdel-RazekR., El-Din AnbarT.Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. Int J Dermatol.2007; 46: 468–74.
14.
PearceD.J., StealeyK.H., BalkrishnanR., FleischerA.B.Jr., FeldmanS.R.Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol.2006; 45: 370–4.
15.
FeldmanS.R.Advances in psoriasis treatment. Dermatology Online Journal at: http://dermatology.cdlib.org/. Accessed August 6, 2011.
16.
HightonA., QuellJ.Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol.1995; 32: 67–72.
17.
ZhuX., WangB., ZhaoG.An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol.2007; 21: 466–72.
18.
BalinA.K., ClarkS.D., FlemingT., FloresJ., GlinertR.J., GraeberM.Calcitriol 3 [micro]g/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol.2007; 6: 428–35.
19.
ScottL.J., DunnC.J., GoaK.L.Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol.2001; 2: 95–120.
20.
PatelB., SiskinS., KrazmienR., LebwohlM.Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol.1998; 38: 1010–11.
21.
LebwohlM., HeckerD., MartinezJ., SapadinA., PatelB.Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol.1997; 37: 93–5.
22.
MenterA., KormanN.J., ElmetsC.A.Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol.2009; 60: 643–59.
23.
GreenC., GanpuleM., HarrisD.Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol.1994; 130: 483–7.
24.
KaurI., DograS., JainR., KumarB.Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol.2008; 74: 471–4.
25.
de KorteJ., van der ValkP.G., SprangersM.A.A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol.2008; 158: 375–81.
26.
ThamS.N., LunK.C., CheongW.K.A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol.1994; 131: 673–7.
27.
CunliffeW.J., Berth-JonesJ., ClaudyA.Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol.1992; 26: 736–43.
28.
BruceS., EpinetteW.W., FunicellaT.Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol.1994; 31: 755–9.
29.
CullenS.I.Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. South Med J.1996; 89: 1053–6.
30.
PoynerT., HughesI.W., DassB.K., AdnittP.Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat.1993; 4: 173–7.
31.
OranjeA.P., MarcouxD., SvenssonA.Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol.1997; 36: 203–8.
32.
DarleyC.R., CunliffeW.J., GreenC.M., HutchinsonP.E., KlaberM.R., DownesN.Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol.1996; 135: 390–3.
33.
LebwohlM., OrtonneJ.P., AndresP., BriantaisP.Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis.2009; 83: 205–12.
34.
MorrisonA., MizziF.Multicenter, open-label, noncomparative long term safety study to assess the local and systemic safety of calcitriol 3 [micro]g/g ointment applied twice daily for up to 52 weeks in subjects suffering from mild to moderate chronic plaque psoriasis.Galderma Research & Development; 2004 Jun. Study Report RD.03.SRE.2663.
35.
OrtonneJ.P., HumbertP., NicolasJ.F.Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 micro g(-1) ointment and calcipotrial 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol.2003; 148: 326–33.
36.
CamarasaJ.M., OrtonneJ.P., DubertretL.Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat.2003; 14: 8–13.
37.
HutchinsonP.E., MarksR., WhiteJ.The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology.2000; 201: 139–45.
38.
HofmannU.B., EggertA.A., BrockerE.B., GoebelerM.Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis. Br J Dermatol.2003; 148: 779–83.
39.
ScarpaC.Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol.1996; 6: 142–6.
40.
VeienN.K., BjerkeJ.R., Rossmann-RingdahlI., JakobsenH.B.Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol: a double-blind trial. Br J Dermatol.1997; 137: 581–6.
41.
BarkerJ.N., AshtonR.E., MarksR., HarrisR.I., Berth-JonesJ.Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol.1999; 141: 274–8.
42.
LebwohlM., SiskinS.B., EpinetteW.A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol.1996; 35: 268–9.
43.
LebwohlM., YolesA., LombardiK., LouW.Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol.1998; 39: 447–50.
44.
LahfaM., MrowietzU., KoenigM., SimonJ.C.Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol.2003; 13: 261–5.
KaufmannR., BibbyA.J., BissonnetteR.A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology.2002; 205: 389–93.
47.
KragballeK., AustadJ., BarnesL.A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol.2006; 154: 1155–60.
48.
van de KerkhofP.C., HoffmannV., AnsteyA.A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol.2009; 160: 170–6.
49.
LugerT.A., CambazardF., LarsenF.G.A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology.2008; 217: 321–8.
50.
PrignanoF., BuggianiG., LottiT.Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. Acta Biomed.2009; 80: 51–6.
51.
NoborioR., KobayashiK., ShintaniY., MoritaA.Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow-band ultraviolet B therapy for the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed.2006; 22: 262–4.
52.
Roussaki-SchulzeA.V., KouskoukisC., KlimiE., ZafiriouE., GalanosA., RallisE.Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. Drugs Exp Clin Res.2005; 31: 169–74.
53.
TorrasH., AliagaA., Lopez EstebaranzJ.L.A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat.2004; 15: 98–103.
54.
WooW.K., McKennaK.E.Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol.2003; 149: 146–50.
55.
MascaroJ.M.Vitamin D and psoralen plus UVA radiation. Cutis.2002; 70: 13–5.
56.
RingJ., KowalzickL., ChristophersE.Calcitriol 3 migrog g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol.2001; 144: 495–9.
57.
RamsayC.A., SchwartzB.E., LowsonD., PappK., BolducA., GilbertM.Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology.2000; 200: 17–24.
58.
MolinL.Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotrial-UVB Study Group. Dermatology.1999; 198: 375–81.
59.
KragballeK.Vitamin D and UVB radiation therapy. Cutis.2002; 70: 9–12.
60.
AshcroftD.M., Li Wan PoA., WilliamsH.C., GriffithsC.E.Combination regimens of topical calcipotriene in chronic plaque psoriasis: systemic review of efficacy and tolerability. Arch Dermatol.2000; 136: 1536–43.
61.
KatzH.I.Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol.1997; 37: S62–8.
